So Jeong Lee, Torben D. Pearson, Maeva Dhaynaut, Alexander C. MacDonagh, Hsiao-Ying Wey, Moses Q. Wilks, Bryan L. Roth, Jacob M. Hooker, Marc D. Normandin
{"title":"Selective Mu-Opioid Receptor Imaging Using 18F-Labeled Carfentanils","authors":"So Jeong Lee, Torben D. Pearson, Maeva Dhaynaut, Alexander C. MacDonagh, Hsiao-Ying Wey, Moses Q. Wilks, Bryan L. Roth, Jacob M. Hooker, Marc D. Normandin","doi":"10.1021/acs.jmedchem.4c02287","DOIUrl":null,"url":null,"abstract":"Carfentanil, a highly potent synthetic opioid, paradoxically serves as a crucial positron emission tomography (PET) imaging tool in neurobiological studies of the mu-opioid receptor (MOR) system when labeled with carbon-11 ([<sup>11</sup>C]CFN). However, its clinical research use is hindered by extreme potency and the limited availability of short-lived carbon-11 (<i>t</i><sub>1/2</sub> = 20.4 min). We present fluorine-18-labeled fluorocarfentanils ([<sup>18</sup>F]FCFNs), which can be produced at higher molar activity, allowing for lower mass doses and benefiting from the longer half-life of fluorine-18 (<i>t</i><sub>1/2</sub> = 109.8 min), facilitating broader accessibility. Using copper-mediated radiofluorination, we synthesized a small [<sup>18</sup>F]FCFN library and conducted preclinical imaging evaluations. Two candidates, <b><i>o</i>-</b><sup><b>18</b></sup><b>F-1</b> and <b><i>p</i>-<sup>18</sup>F-2</b>, showed optimal brain uptake, favorable pharmacokinetics, and high MOR-specific binding. Selectivity was confirmed through in vitro binding assays and in vivo PET scans. These [<sup>18</sup>F]FCFNs are promising for accessible human brain MOR imaging.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"79 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02287","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Carfentanil, a highly potent synthetic opioid, paradoxically serves as a crucial positron emission tomography (PET) imaging tool in neurobiological studies of the mu-opioid receptor (MOR) system when labeled with carbon-11 ([11C]CFN). However, its clinical research use is hindered by extreme potency and the limited availability of short-lived carbon-11 (t1/2 = 20.4 min). We present fluorine-18-labeled fluorocarfentanils ([18F]FCFNs), which can be produced at higher molar activity, allowing for lower mass doses and benefiting from the longer half-life of fluorine-18 (t1/2 = 109.8 min), facilitating broader accessibility. Using copper-mediated radiofluorination, we synthesized a small [18F]FCFN library and conducted preclinical imaging evaluations. Two candidates, o-18F-1 and p-18F-2, showed optimal brain uptake, favorable pharmacokinetics, and high MOR-specific binding. Selectivity was confirmed through in vitro binding assays and in vivo PET scans. These [18F]FCFNs are promising for accessible human brain MOR imaging.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.